A first-generation ALK TKI, crizotinib, was shown to significantly improve PFS and ORR in both first- and second-line settings in patients with ALK-rearranged NSCLC, compared to chemotherapy (32, 33). This evidence concerns the gene ALK and non-small cell lung carcinoma.